|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes|
|Rapid review commissioned||12/03/2018|
|Rapid review completed||10/04/2018|
|Rapid review outcome||A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.|
The HSE has approved reimbursement September 2018.